HIVST PRODUCTS Sample Clauses

HIVST PRODUCTS. As of December 2020, there are four WHO prequalified (PQ) HIVST products: the INSTI HIV Self-Test (Bioanalytical, Canada); the Mylan HIV Self-Test (Mylan, Atomo Diagnostics, Australia); and the OraQuick HIV Self-Test (OraSure Technologies, USA) and the SURE CHECK HIV 1/2 Assay (Chembio, USA), and several others may be expected to come to market.19 An additional six HIV self-tests have been approved by a stringent regulatory authority in one of the founding member countries of the International Medical Device Regulators Forum (IMDRF) or recommended for procurement by the Unitaid/GF EPRD.20 Additional locally manufactured HIVST kits with national-level approval have emerged in some countries (six products identified), including Belarus, Brazil and Nigeria. The quality and performance of these products are largely unknown. There are other HIV self-tests under development, using either whole blood specimens, oral fluid specimens or urine specimens. Despite this encouraging progress toward international approvals, manufacturers remain concerned that in some countries the regulatory process remains opaque, with a lack of clarity about which authorities are responsible for the registration of HIVST products and lengthy in-country validation and registration processes for products even after they have achieved WHO PQ status. Table 1 lists those that have either been prequalified by WHO, approved by a regulatory authority in one of founding-member countries of the International Medical Device Regulators Forum or eligible for procurement on recommendation of the Unitaid/Global Fund EPRD.
AutoNDA by SimpleDocs
HIVST PRODUCTS. Selection of which HIVST products to use must first take account of the regulatory situation in the country, whether there are already regulations governing the use of medical devices or, if not, which substitute regulatory body’s decisions will be used instead. Your situational analysis and additional operational research should also have generated data on the preferences of your target populations for various different types of test kits and culture-specific issues, which will influence product choices. Regardless of the final decision, all HIVST products should have been assessed and approved by a recognized national authority and/or an international body such as WHO, or a founding member of the Global Harmonization Task Force on Medical Devices. This will ensure the procurement of quality HIVST products without expensive and lengthy in- country validation studies. Choose products with acceptable specifications, including adequate sensitivity (proportion of people with the disease correctly identified as reactive by the test) and specificity (proportion of people without the disease correctly identified as non- reactive) of above 95%. HIVST products should be highly sensitive and specific, so that the results are accurate, be simple to use; include all necessary consumables; provide results that are easy to read/interpret within a short period of time and contain clear pictorial instructions and support tools (including information on what to do and where to go after self-testing. HIVST kits should be easy to use. Sample preparation should be simple and only a small number of operator steps, especially timed steps, should be required to perform the test. Each step for HIV testing, from the specimen collection to interpreting the final result, is critical for ensuring a correct result. The more steps, the greater the risk is for user error, which may in turn increase the risk of an incorrect test result. Collecting and transferring specimen has been shown to be particularly prone to error for self-testers, resulting in test system failures, invalid results and suboptimal performance. Thus, an HIV RDT for self-testing with few steps, or ideally one single step, could substantially reduce the risk of a number of user errors. An ideal RDT for self-testing should provide a result in one to twenty minutes and have a read-window where results are stable for more than 60 minutes, after which they give an invalid result. Result windows should be clear and easy t...

Related to HIVST PRODUCTS

  • Products Products available under this Contract are limited to Software, including Software as a Service, products and related products as specified in Appendix C, Pricing Index. Vendor may incorporate changes to their product offering; however, any changes must be within the scope of products awarded based on the posting described in Section 1.B above. Vendor may not add a manufacturer’s product line which was not included in the Vendor’s response to the solicitation described in Section 1.B above.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

Time is Money Join Law Insider Premium to draft better contracts faster.